

DOI: 10.53555/ks.v12i4.3837

Impact Of Glutathione Peroxidase On Michigan Neuropathy Scale And Nottingham Health Profile In Type 2 Diabetes Mellitus Patients With Neuropathy: A Cross-Sectional Study

Farzana Khan¹, Syed Hamid Habib^{2*}, Muhammad Omar Malik³, Aziz ul Hassan Aamir⁴, Abdul Basit⁵, Amber Javaid⁶

¹Physiology Department, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar Pakistan. Physiology Department, Peshawar Medical College, Peshawar, Riphah International University Islamabad, Pakistan

²Physiology Department, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar Country: Pakistan.

³Physiology Department, Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.

⁴Endocrinology Unit, Hayatabad Medical Complex, Peshawar, Pakistan.

⁵Research Officer, Rehman Medical Institute, Khyber Medical University, Peshawar, Pakistan.

⁶Pharmacology Department, Peshawar Medical College. Peshawar, Riphah International University Islamabad, Pakistan

***Corresponding author:** Syed Hamid Habib,

*Physiology Dept. Institute of Basic Medical Sciences, Khyber Medical University, Peshawar, Pakistan.

Email: dr.hamidhabib@gmail.com

Abstract

Background: Diabetic peripheral Neuropathy (DPN) is the most common complication of Type-2 Diabetes Mellitus (T2DM), affecting almost 50% of all the T2DM patients. DPN has been associated with increase in Disability adjusted life years and decreased Quality of life.

Methods: A cross sectional study was conducted at Hayatabad Medical complex Peshawar, in n=88 T2DM patients from January to August 2023 with ethical approval letter DIR/KMU-ASB&RB/AR/001998. Patients were assessed with Michigan neuropathy scale (history and physical) and Nottingham health profile questionnaire. Glutathione peroxidase (GPX), Malondialdehyde (MDA) levels, Superoxide dismutase (SOD), HbA1c, serum creatinine, and Vitamin B12 levels were recorded from the laboratory records of the patients.

Results: Results reported Significant association of GPX with MDA (P=0.041), and Michigan neuropathy score (P=0.036). Regression model reported significant impact of GPX on Pain (P=0.035, CI 88.11-94.84) and Sleep (P=0.002, CI 0.760-12.698) in patients with T2DM. the combined effect of GPX and SOD and GPX and Vitamin B12 was not significant. MAD concentration in the studied sample was 6.92µM, IQR: 2.745, SOD 94.45 U/mL, IQR: 39.95 and GPX 51.91 U/gHb reported. MDA was elevated in 93%, decreased SOD in 80.6% and decreased GPX was reported in 72.7% of the patients.

Conclusion: the concentration of Antioxidants GPX and SOD was decreased and MDA was elevated in T2DM patients. T2DM patients with lower GPX may report higher score on Michigan neuropathy assessment. Concentration of GPX in Diabetic patients can be found associated with pain and disturbed sleep patterns.

Keywords: Diabetes mellitus. Glutathione peroxidase, Malondialdehyde, diabetic neuropathy, Michigan neuropathy assessment, Nottingham health profile.


Introduction

Diabetic Peripheral Neuropathy (DPN) is one of the most common and progressively disabling health conditions caused by Diabetes Mellitus (DM) and Type-2 Diabetes Mellitus (T2DM). Prevalence of DM has been growing worldwide exceeding from 200 million cases in 1990 to 830 million in 2022, increasing in lower middle-income and higher-income countries[1]. T2DM is the most common type of diabetes among older adults and makes up 96% of the total diabetes prevalence worldwide[2] DM can lead to several systemic diseases which increase the risks of hospitalization, increase in healthcare costs. In 2019, Disability Adjusted life years (DALYs) associated with T2DM were counted as 66.3 million, with 801.5 DALYS/100,000 population, with 26.7% of increase since 1990[3]. The burden of diabetes is consecutively increasing within developing countries due to increase in sedentary lifestyles, diet modifications, and genetic and hereditary susceptibilities[4]. According to 2021 estimates, Pakistan ranks 3rd in world diabetes prevalence, with 33 million of the population being diabetic, approximately 26.7% of the country living residents[5,6]

Diabetes is associated with multiple complications and comorbidities which progressively impact health and quality of life (QoL) in diabetic patients[7] Although, regular exercise, changes in lifestyle exercise routine and medicinal management have improved QoL in diabetic patients[8]. DPN can be caused by many factors including older age, comorbidities like hypertension, poor glycaemic control, long history of diabetes, peripheral vascular disease and excessive alcohol consumption[9,10]. DPN is defined as “the presence of symptoms and/or signs of peripheral nerve dysfunction in people

with diabetes after the exclusion of other causes”[11]. DPN causes symmetrical paraesthesia, loss of sensation and hyperalgesia and can lead to severe complications of foot ulcerations, gangrene, and amputations in diabetic patients[12]. Prevalence of DPN in Type 1 diabetes has been reported as 29.1%, and 42.2% to 50% in T2DM patients, with DPN-related pain in 20% of diabetic patients[10,13]

The pathophysiology of DPN is considered to be caused by the mixed interplay of hyperglycaemia, dyslipidaemia and insulin resistance, with alterations in mitochondrial functions, inflammation and oxidative stress[14]. The overproduction of reactive oxygen species (ROS) or the deregulation of antioxidant systems leads to oxidative damage in DPN, thus novel therapeutics are focused on targeting oxidative stress in treating DPN [15]. In Oxidative stress, the amount of free radicals in the body exceeds the number of antioxidants that can eliminate them, while impaired glucose metabolism in diabetes, and excess glucose concentrations lead to excessive accumulation of toxic metabolites, leads to mitochondrial injury and excretion of ROS[16,17]. The most common oxidative stress biomarkers in DPN have been reported to be Malondialdehyde, Thiobarbituric acid reactive substances, and 8-hydroxydeoxyguanosine, while superoxide anions, hydrogen peroxide and hydroxyl radicals are common free radicals associated with development of DPN[18,19] Impacts of oxidative stress are mitigated by natural and synthetic antioxidants like glutathione, Vitamin C and E, Phenolic acids, butylated hydroxyanisole and hydroxytoluene[20–23]. Antioxidants repair or remove the damaged biomolecules from the body caused by ROS, before their accumulation leads to altered cellular metabolism and irreversible damage. The biologically found antioxidants are superoxide dismutase (SOD), catalase, Glutathione peroxidase (GPx), Glutathione (GSH) and some types of proteins[24]. Patients with T2DM have been reported to have lower concentrations of GPx and thus were reported with higher concentrations of ROS[25] GPx is a selenium-containing antioxidant enzyme which catalyses the reduction of hydrogen peroxide and organic hydroperoxides using glutathione (GSH) as hydrogen donor. GPx metabolizes hydrogen peroxide by oxidizing the tripeptide GSH into an oxidized form (GSSG)[26].



Aim of the current was to find out the impact of GPX on DPN in patients with T2DM and to evaluate the impact of GPX on Michigan neuropathy assessment scale and Nottingham health profile as an important antioxidant against ROS.

Methods

The current study is part of a randomised controlled trial approved by the Advanced Study and Research Board of Khyber Medical University, approval letter DIR/KMU-ASB&RB/AR/001998. Ethical approval was issued by the Institution Ethical Review Committee approval number KMU/IBMS/IRBE fourth meeting 2023/9821-21. All the study procedures and protocols were carried out in adherence with the institutional regulations and guidelines, Declaration of Helsinki, and Good Clinical Practice guidelines. The trial was registered with clinicaltrial.gov, registration number NCT06131918. The study included n=100 T2DM patients diagnosed according to American diabetic association guidelines and patients were enrolled in the study from the endocrinology department of Hayatabad Medical Complex (HMC) upon patient verbal and written consent of voluntary participation. Patients were assessed for systolic and diastolic blood pressure, and Michigan Neuropathy history and physical assessment scale were utilised for assessing complications related to diabetes, and responses were recorded in to SPSS (Statistical package for social sciences) version 26. Patients’ energy level, pain, emotional reaction, sleep, social isolation and physical abilities were assessed through Nottingham scale. Vitamin B12 (Cobalamin), haemoglobin, alkaline transferase, serum creatinine, glycated haemoglobin (HbA1c), GPx level, superoxide dismutase, Malondialdehyde and levels of superoxide anions were included in the labs. Patients upon receiving in the endocrinology department were confirmed for diabetes through routine lab tests. The inclusion criteria included confirmed diagnosis of diabetes, at least a year of diabetic history, minimum eighteen years old and agreed for voluntarily participation in the study. Upon verbal and written consent, Patients was assessed for systolic and diastolic blood pressure, Michigan neuropathy history and physical assessment were performed followed by Nottingham scale parameters. Laboratory reports of the patients were analysed and findings required for the study were recorded in SPSS. Michigan Neuropathy Screening Instrument (MNSI) was used for evaluation of history and physical assessment of neuropathy in study participants. For history score of >4 was considered as eligible for neuropathy and for physical assessment of neuropathy score of >2.5 was considered as cut-off point for neuropathy assessment.

Results

Current study was conducted in n=88 diabetic patients with dominant female sample including 55.7% (49/88) female and 44.3% (39/88) male patients. Mean age of the participants was 52.19±7.6 years and 74% of participants were in the age group of 46-60 years thus comprising mainly the late adult population. Mean BMI was 27.49±3.95 kg/m², 63.6% of patients were having moderate physical activity occupation, 69.3% of patients were diabetic only and 30.7% were diabetic and hypertensive as given in Table I.

Table I: Sociodemographic parameters of Type II Diabetic patients diagnosed with neuropathy.

Variables	Frequency	%	Mean	Significance with GPx
Gender	Male: 39	44.3		0.756
	Female: 49	55.7		
Age	18-30 years:1	1.1	52.19±7.6	0.949
	31-45 years:19	21.6		
	46-60 Years:65	73.9		
	61 years & above:3	3.4		

BMI	Underweight: 0 Healthy weight 27: Overweight: 36 Obesity class I: 22 Obesity class II: 2 Obesity class III: 1	0 27 36 22 2 1	27.49±3.95	0.193
Occupation	Strenuous physical:17 Moderate physical:56 Sedentary:15	19.3 63.6 17.0		0.798 0.664 0.998
Co-morbidities	Diabetic Only: 61 Diabetic and hypertensive:27	69.3 30.7		0.180
Diabetes history in years	Less than 5 years: 23 6-10 years: 44 11 years and above:21	26.1 50.0 23.9	8.78±4.2	0.937
Malondialdehyde	Low concentration: 2 Normal concentration: 4 High concentration:55 Very high concentration: 27	2.3 4.5 62.5 30.7	Median: 6.92µM, IQR:2.745	0.041
Superoxide dismutase	Low concentration:71 Normal concentration: 7 High concentration:10	80.6 8.0 11.4	94.45 U/mL, IQR:39.95	0.083
Glutathione peroxidase(GPX)	Low concentration:64 Normal concentration: 16 High concentration:8	72.7 18.2 9.1	51.91 U/gHb	
HbA1c (%)	Pre-Diabetes 4 Diabetes 84	4.5 95.5	10.20±2.56	0.354
Serum creatinine	Low: 24 Normal: 57 High: 7	27.3 64.8 8.0	0.928mg/dL±0.20	0.231
Haemoglobin	Low: 32 Optimal: 56	36.4 63.6	13.60±1.57	0.377
Vitamin B12	Borderline:46 Normal:42	52.3 47.7	291.7±70.15 pg/ml	0.248
Michigan neuropathy History			10.557±0.980	0.571
Michigan neuropathy Physical assessment			7.580±1.393	0.036
Nottingham Health Profile				
Energy			97.81±6.93	0.747
Pain			93.71±10.32	0.221
Emotional Reactions			52.70±25.37	0.499
Sleep			69.45±14.60	0.998
Social isolation			64.67±13.49	0.065
Physical Abilities			43.68±7.55	0.270

Data was collected and analysed for 88 participants, 44.3% (39/88) male, and 55.7% (49/88) were female. Due to non-normal distribution of data Spearman Rho was applied for association between the sociodemographic variables and its association with GPX concentration. Gender, age, BMI, occupation, co-morbidities, diabetes history in years, superoxide dismutase, HbA1c, serum creatinine, haemoglobin levels, and vitamin B12 levels did not reported significant association with GPX. Levels of MDA were reported to have significant association (P=0.041), P<0.05. Michigan neuropathy physical assessment (P=0.036), P<0.05 was significant with levels of GPX in the patients Table I.

The six factors of Nottingham health profile energy levels, pain, emotional reactions, sleep, social isolation and physical abilities none reported significant association with GPX as shown in Table II.

Table II: Regression model of Glutathione peroxidase levels with Nottingham health profile and Michigan Neuropathy score

SN	variables	Intercept constant	Significance	Confidence interval	
				Lower bound	Upper bound
1	Energy level	97.452	0.554	95.064	99.545
2	Pain	91.653	0.035*	88.116	94.841
3	Emotional reaction	43.898	0.332	41.447	58.473
4	Social isolation	69.254	0.909	64.090	74.781
5	Sleep	6.446	0.002*	0.760	12.698
6	Physical abilities	42.611	0.386	39.925	45.498
7	GPX and VitaminB12	7.995	0.088	7.522	8.601
8	GPX and Superoxide dismutase	7.814	0.009	7.471	8.118

GPX was reported to have protective effect on neuropathy in patients with diabetes, in the absence of GPX the intercept constant value of 8.053 was the neuropathy score. The GPX coefficient -0.009 suggested that for every 1 unit increase in GPX levels the neuropathy score decreased by 0.009 units. The relationship was significant at P=0.036, P<0.05. Bootstrap

analysis for coefficients reported significant positive association between pain ($P=0.035$), $P<0.05$ and GPX. The sleep factor in the Nottingham health profile was reported to have significant linear association ($P=0.002$), $P<0.05$ for GPX. The combined effect of GPX and Vitamin B12 was tested for its protective role in diabetic neuropathy, which was not significant. The combined effect of GPX and Superoxide dismutase ($P=0.009$), $P<0.05$ was reported significant, lowering neuropathy scores on the Michigan scale.

Discussion

Among the studied $n=88$ T2DM patients laboratory reports were analysed for MAD, SOD, GPX, HbA1C, Serum creatinine, Haemoglobin and Vitamin B12 concentrations. Concentrations of GPX has been reported to 196 to 477 μmol in Plasma, 49 to 93 U/gHb in erythrocytes and 52 to 96 U/gHb in whole blood[27]. for current study GPX concentration was assessed in the whole blood thus low concentration was considered as <51 U/gHb, normal range was considered as 52 to 96 U/gHb and higher concentration was termed as >96 U/gHb. Findings of the current study reported low concentrations of GPX 51.91 U/gHb, lower than the 52 to 96 U/gHb of normal range. Antioxidants activity in patients with T2DM has been reported to be lower overtime and decreased GPX has been found in T2DM after ten years of the disease[28], although in findings of the current study no significant association was reported between GPX and duration of diabetes. GPX was reported to have significant association with Michigan neuropathy physical; assessment scale ($P=0.036$), while for the factors of Nottingham health profile Energy ($P=0.747$), pain (0.221), emotional reactions (0.499), sleep (0.998), social isolation (0.065) and physical abilities (0.270), none of the values were found significant in the correlation. Although the regression model reported GPX significant association with Michigan neuropathy score ($P=0.036$), Nottingham pain level ($P=0.035$), and Sleep ($P=0.002$). The combined effect of GPX and vitamin B12 and GPX and SOD were not found significant. While empirical research has reported that GPX being a prominent antioxidant may have physiological processes responsible for pain modulation, and may play a critical role in pain management[29]. While the ROS leads to cellular destruction, it also initiates or exacerbates the inflammatory responses thus enabling the pain cycle[30]. while disturbed sleep patterns in the animal models have been reported to be cause of imbalance antioxidants[31], which in the context of the current study can be found decreased GPX and SOD concentrations in the patients with T2DM. While disturbed sleep patterns in the T2DM population has been found to be caused by lowered levels of GPX and increased concentrations of MDA concentrations[32], consecutively reported in the studied sample of the current study where MDA concentrations were in 93% and decreased GPX concentrations in 72% of patients.

MDA mean concentration was reported 6.92 μM , IQR:2.745, with 93.7% of patients reported high and very concentrations as compared to standard range of 2.0 to 4.0 μM [33,34]. MDA concentration has been reported to be in the range of 2.0 to 4.0 μM , in different studies[33,34], for current study MDA levels were defined as low concentration (less than 2.0 μM), normal concentration (2.0-4.0 μM), high concentration (4.1-8.0 μM) and more than 8.0 μM as very high concentration. Findings of the current study reported MDA mean concentration of 8.85 $\mu\text{M}\pm 6.48$, which is higher than the standard average of very high concentration. SOD is a metalloenzymatic chemical working as antioxidant and mitigates the impacts of oxidative stress thus reported to have protective mechanism in patients with DPN, while lower levels of SOD has been reported in patients with DPN[35] Normal concentrations of SOD in healthy controls has been reported to be in the range of 149.70-207.10 U/mL with 95% of confidence interval, for current study this range was defined as the normal range, and values below or above this range were defined as low and high levels of SOD[36] in the studied sample SOD concentration was 94.45 U/mL, IQR:39.95, reported very low than the normal mean concentrations.

As Physical activities has a significant impact on T2DM and habitual aerobic exercises has been reported to be helpful in glycaemic control[37], participants of the current study were grouped in the occupation categories of strenuous, moderate and sedentary physical activities, based on the type and intensity of physical activity associated with occupation. Although HbA1c levels and GPX in the studied sample did not reported significant association with type of physical activity in the occupation categories, which is contrary to the empirical evidence as many studies has reported significant association between T2DM levels and physical activity[38].while regular physical activity has been reported to increase GPX levels, which was not found significant by current study[39]. Although, outdoor physical activities are an important aspect of glycaemic control and activities related to occupation may not be sufficient to find out the impact of physical activity on HbA1c levels or GPX [40].

SOD association with GPX was not significant ($P=0.083$) reported by current study, although SOD and GPX has been reported to be protectors against oxidative stress in patients with DPN [41]. in the current study the combined effect of GPX and SOD was also tested for its efficacy in preventing DPN in T2DM patients, the combined model was not found significant ($P=0.009$). Low concentrations of SOD and GPX has been consecutively reported in the literature to be found in patients with DPN, and it was parallel with findings of the current study, where both SOD and GPX concentrations were reported 94.45 U/mL and 51.91 U/gHb, lower than the standard concentrations of 149.70-207.10 U/mL and 52 to 96 U/gHb respectively.

There was no significant difference in the male and female gender and level of GPX ($P=0.765$), age categories and level of GPX ($P=0.840$), BMI categories and GPX level ($P=0.107$), and Occupation categories ($P=0.621$). MDA levels had significant positive association ($P=0.041$) with GPX levels, while the association between MDA and GPX has been reported variability in the empirical evidence. It has been reported significant and negative association in workers exposed to benzene concentrations[42]. While MDA levels has been reported to be lower than GPX levels in patients with T2DM, although no significant association was reported between MDA and GPX[43]. In children with chronic hepatitis, MDA and GPX were reported to have significant association, while results of the current study can be found relevant with findings of a study,

where diabetic rates showed positive association of MAD and GPX as compared to control groups of non-diabetic rats[44,45].

Conclusion

Patients with type 2 Diabetes mellitus has elevated concentration of the oxidative stress factors Malondialdehyde and decreased amount of Glutathione peroxidase and Superoxide dismutase. MDA and GPX were reported to have positive association, significant association of GPX with Michigan neuropathy assessment, and significant association of GPX with pain and sleep factors of the Nottingham health profile.

Funding: This research was partially funded by a research grant from ORIC Khyber Medical University Peshawar. DIR/ORIC/Ref/24/00062.

Authors' Contribution

- 1. F.K:** Concept, design, and conduct of the study. Writing of the first draft of the manuscript. Edited, reviewed and approved the final version of the manuscript. The author confirm that no paper mill and artificial intelligence was used.
- 2. S.H.H:** Concept and designed the study. Overall Supervision and Guarantor of the study Edited, reviewed, and approved the final version of the manuscript. The author confirm that no paper mill and artificial intelligence was used.
- 3. M.O.M:** Data curation, formal analysis, and visualization. Edited, reviewed, and approved the final version of the manuscript. The author confirm that no paper mill and artificial intelligence was used.
- 4. A.H.A:** Data collection and analysis. Edited, reviewed, and approved the final version of the manuscript. The author confirm that no paper mill and artificial intelligence was used.
- 5. A.B:** Statistical analysis. Edited, reviewed and approved the final version of the manuscript. The author confirm that no paper mill and artificial intelligence was used.
- 6. A.J:** Article search and literature review. The author confirm that no paper mill and artificial intelligence was used.

Human Ethics and Consent to Participate Declaration

This study was conducted in accordance with the ethical standards of the Advanced Study and Research Board of Khyber Medical University Peshawar Pakistan , and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Prior to participation, all participants were informed of the nature, purpose, and potential risks of the study. Written informed consent was obtained from all individual participants included in the study. Participation was voluntary, and participants were informed that they could withdraw from the study at any time without any negative consequences.

Confidentiality and anonymity of the participants have been preserved throughout the study. All personal data have been securely stored and used solely for the purposes of this research.

The format of the consent form signed by the participants is attached.

References

1. World Health Organization. Diabetes [Internet]. World Health Organization. 2022 [cited 2025 Mar 12]. Available from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
2. Global Burden of Diseases. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *Lancet*. 2023 Jul 15;402(10397):203–34.
3. Safiri S, Karamzad N, Kaufman JS, Bell AW, Nejadghaderi SA, Sullman MJM, et al. Prevalence, Deaths and Disability-Adjusted-Life-Years (DALYs) Due to Type 2 Diabetes and Its Attributable Risk Factors in 204 Countries and Territories, 1990-2019: Results From the Global Burden of Disease Study 2019. *Front Endocrinol (Lausanne)*. 2022 Feb 25;13:838027.
4. Misra A, Gopalan H, Jayawardena R, Hills AP, Soares M, Reza-Albarrán AA, et al. Diabetes in developing countries. *J Diabetes*. 2019 Jul;11(7):522–39.
5. Bhatti W. 'Pakistan ranks 3rd in prevalence of diabetes in world after China and India' [Internet]. 2021 [cited 2025 Mar 12]. Available from: <https://www.thenews.com.pk/print/899124-pakistan-ranks-3rd-in-prevalence-of-diabetes-in-world-after-china-and-india>
6. Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: A silent killer. *Ann Med Surg (Lond)*. 2022 Jun 3;79:103901.
7. Garg P, Duggal N. Type 2 diabetes mellitus, its impact on quality of life and how the disease can be managed-a review. *Obesity Medicine*. 2022 Oct 1;35:100459.
8. Tamornpark R, Utsaha S, Apidechkul T, Panklang D, Yeemard F, Srichan P. Quality of life and factors associated with a good quality of life among diabetes mellitus patients in northern Thailand. *Health and Quality of Life Outcomes*. 2022 May 20;20(1):81.
9. Bodman MA, Dreyer MA, Varacallo MA. Diabetic Peripheral Neuropathy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Mar 12]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK442009/>

10. Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative “diabetes and nerves.” *Endocrine and Metabolic Science*. 2020 Jul 1;1(1):100053.
11. Yu Y. Gold Standard for Diagnosis of DPN. *Front Endocrinol (Lausanne)*. 2021 Oct 26;12:719356.
12. Pop-Busui R, Ang L, Boulton AJM, Feldman EL, Marcus RL, Mizokami-Stout K, et al. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy [Internet]. Arlington (VA): American Diabetes Association; 2022 [cited 2025 Mar 12]. (ADA Clinical Compendia Series). Available from: <http://www.ncbi.nlm.nih.gov/books/NBK580224/>
13. Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. *Curr Diab Rep*. 2019 Aug 27;19(10):86.
14. Zhu J, Hu Z, Luo Y, Liu Y, Luo W, Du X, et al. Diabetic peripheral neuropathy: pathogenetic mechanisms and treatment. *Front Endocrinol (Lausanne)*. 2024 Jan 9;14:1265372.
15. Lin Q, Li K, Chen Y, Xie J, Wu C, Cui C, et al. Oxidative Stress in Diabetic Peripheral Neuropathy: Pathway and Mechanism-Based Treatment. *Mol Neurobiol*. 2023 Aug;60(8):4574–94.
16. NIH, National cancer Institute. Definition of oxidative stress - NCI Dictionary of Cancer Terms - NCI [Internet]. 2011 [cited 2025 Mar 12]. Available from: <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oxidative-stress>
17. Pang L, Lian X, Liu H, Zhang Y, Li Q, Cai Y, et al. Understanding Diabetic Neuropathy: Focus on Oxidative Stress. *Oxidative Medicine and Cellular Longevity*. 2020;2020(1):9524635.
18. S S, Hegde SV, Agarwal SV, NS D, Pillai A, Shah SN, et al. Biomarkers of Oxidative Stress and Their Clinical Relevance in Type 2 Diabetes Mellitus Patients: A Systematic Review. *Cureus*. 2024;16(8):e66570.
19. Basu P, Averitt DL, Maier C, Basu A. The Effects of Nuclear Factor Erythroid 2 (NFE2)-Related Factor 2 (Nrf2) Activation in Preclinical Models of Peripheral Neuropathic Pain. *Antioxidants (Basel)*. 2022 Feb 21;11(2):430.
20. Singh B, Singh JP, Kaur A, Singh N. Phenolic composition, antioxidant potential and health benefits of citrus peel. *Food Res Int*. 2020 Jun;132:109114.
21. Savira M, Sari DK, Machrina Y, Widjaja SS, Unitly AJA, Ilyas S, et al. Effect of Garlic Ethanol Extract Administration on Glutathione Levels to Prevent Oxidative Stress in Smoker Rat Model. *Med Arch*. 2023;77(6):418–21.
22. Doseděl M, Jirkovský E, Macáková K, Krčmová LK, Javorská L, Pourová J, et al. Vitamin C-Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination. *Nutrients*. 2021 Feb 13;13(2):615.
23. Miyazawa T, Burdeos GC, Itaya M, Nakagawa K, Miyazawa T. Vitamin E: Regulatory Redox Interactions. *IUBMB Life*. 2019 Apr;71(4):430–41.
24. Poljsak B, Šuput D, Milisav I. Achieving the Balance between ROS and Antioxidants: When to Use the Synthetic Antioxidants. *Oxidative Medicine and Cellular Longevity*. 2013;2013(1):956792.
25. Altuhafi A, Altun M, Hadwan MH. The Correlation between Selenium-Dependent Glutathione Peroxidase Activity and Oxidant/Antioxidant Balance in Sera of Diabetic Patients with Nephropathy. *Rep Biochem Mol Biol*. 2021 Jul;10(2):164–72.
26. Kuyvenhoven JP, Meinders AE. Oxidative stress and diabetes mellitus Pathogenesis of long-term complications. 1999;
27. Alegria A, Barberá R, Clemente G, Farré R, García MJ, Lagarda MJ. Selenium and glutathione peroxidase reference values in whole blood and plasma of a reference population living in Valencia, Spain. *J Trace Elem Med Biol*. 1996 Dec;10(4):223–8.
28. Dworzański J, Strycharz-Dudziak M, Kliszczewska E, Kielczykowska M, Dworzańska A, Drop B, et al. Glutathione peroxidase (GPx) and superoxide dismutase (SOD) activity in patients with diabetes mellitus type 2 infected with Epstein-Barr virus. *PLOS ONE*. 2020 Mar 25;15(3):e0230374.
29. Fan S, Wang K, Zhang T, Deng D, Shen J, Zhao B, et al. Mechanisms and Therapeutic Potential of GPX4 in Pain Modulation. *Pain Ther*. 2025 Feb 1;14(1):21–45.
30. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. *Pain*. 2020 Sep;161(9):1976–82.
31. Everson CA, Laatsch CD, Hogg N. Antioxidant defense responses to sleep loss and sleep recovery. *Am J Physiol Regul Integr Comp Physiol*. 2005 Feb;288(2):R374–383.
32. Gulec M, Ozkol H, Selvi Y, Tuluçe Y, Aydin A, Besiroglu L, et al. Oxidative stress in patients with primary insomnia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 2012 Jun 1;37(2):247–51.
33. Tsikas D, Tsikas SA, Mikuteit M, Ückert S. Circulating and Urinary Concentrations of Malondialdehyde in Aging Humans in Health and Disease: Review and Discussion. *Biomedicines*. 2023 Oct 10;11(10):2744.
34. Toto A, Wild P, Graille M, Turcu V, Crézé C, Hemmendinger M, et al. Urinary Malondialdehyde (MDA) Concentrations in the General Population—A Systematic Literature Review and Meta-Analysis. *Toxics*. 2022 Mar 29;10(4):160.
35. for the GDS Group, Strom A, Kaul K, Brüggemann J, Ziegler I, Rokitta I, et al. Lower serum extracellular superoxide dismutase levels are associated with polyneuropathy in recent-onset diabetes. *Exp Mol Med*. 2017 Nov;49(11):e394–e394.
36. Jia G, Yan C e, Wu Zong Y, Freng C. Reference Range of Serum Superoxide Dismutase in Healthy Adults and Its Relationship with Sex and Age. *Labeled Immunoassays and Clinical Medicine*. 2017 Apr 25;24(4):366–8.
37. Syeda USA, Battillo D, Visaria A, Malin SK. The importance of exercise for glycemic control in type 2 diabetes. *American Journal of Medicine Open*. 2023 Jun 1;9:100031.
38. Harrington D, Henson J. Physical activity and exercise in the management of type 2 diabetes: where to start? *Practical Diabetes*. 2021;38(5):35–40b.

39. Francisco Javier O, Manuel R, Manuel RR. Regular physical activity increases glutathione peroxidase activity in adolescents with Down syndrome. *Clin J Sport Med*. 2006 Jul;16(4):355–6.
40. Richardson MB, Chmielewski C, Wu CYH, Evans MB, McClure LA, Hosig KW, et al. The effect of time spent outdoors during summer on daily blood glucose and steps in women with type 2 diabetes. *J Behav Med*. 2020 Oct;43(5):783–90.
41. Ighodaro OM, Akinloye OA. First line defence antioxidants-superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX): Their fundamental role in the entire antioxidant defence grid. *Alexandria Journal of Medicine*. 2018 Dec 1;54(4):287–93.
42. Tualeka AR, Martiana T, Ahsan A, Russeng SS, Meidikayanti W. Association between Malondialdehyde and Glutathione (L-gamma-Glutamyl-Cysteinyl-Glycine/GSH) Levels on Workers Exposed to Benzene in Indonesia. *Open Access Maced J Med Sci*. 2019 Apr 12;7(7):1198–202.
43. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. *Ann Clin Biochem*. 2005 Mar;42(Pt 2):99–104.
44. Khedr MA, El-Araby HA, Konsowa HAS, Sokar SS, Mahmoud MF, Adawy NM, et al. Glutathione peroxidase and malondialdehyde in children with chronic hepatitis C. *Clin Exp Hepatol*. 2019 Mar;5(1):81–7.
45. Qujeq D, Aliakbarpour HR, Kalavi K. Relationship between malondialdehyde level and glutathione peroxidase activity in diabetic rats. *Clin Chim Acta*. 2004 Feb;340(1–2):79–83.